CogLinks model reveals how the brain adapts to changing rules
Every day, your brain makes thousands of decisions under uncertainty. Most of the time, you guess right. When…
New insights can reshape psychiatric practice across continents
In a compelling Genomic Press Interview published today in Genomic Psychiatry, Dr. Bruce M. Cohen discusses results and…
Harnessing AI tools for better treatment of serious mental illnesses
Serious mental illnesses (SMI) take a tremendous toll on individuals, their friends and family, and society as a…
Where you live may affect your mental illness risk
Share this Article You are free to share this article under the Attribution 4.0 International license. Living in…
BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia
BioXcel Therapeutics BXCL501 demonstrated a significant mean reduction in mCGI-S score from baseline compared to placebo at 2…
Rapid neuronal evolution linked to high prevalence of autism in humans
A new paper in Molecular Biology and Evolution, published by Oxford University Press, finds that the relatively high…
Why schizophrenia may be ‘the most devastating of mental illnesses’
For Henry Cockburn, the onset of schizophrenia felt like pure common sense.It was February 2002, and the 20-year-old…
New gift expands mental illness studies at Poitras Center for Psychiatric Disorders Research | MIT News
One in every eight people — 970 million globally — live with mental illness, according to the World…
Mental Health Disorders Slash Life Expectancy By Up To 20 Years
Mental health disorders could be a driving factor in heart-related deaths. (© pixelheadphoto – stock.adobe.com) Study Shows Anxiety,…
BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®
BioXcel Therapeutics BXCL501 achieved SERENITY At-Home’s primary endpoint of being well tolerated in the at-home treatment of agitation…
Cardiovascular outcomes worsen in patients with mental health conditions
Every 34 seconds, someone in the United States dies from heart disease. As nearly half of the country suffers from…
BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
BioXcel Therapeutics Data from more than 2,600 agitation episodes collected Topline data readout is on track for August …